Search General Info
Search Education
Search Partnering Companies
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
PharmAbcine Inc. is a clinical stage public company developing next generation antibody therapeutics for oncology, ophthalmology (neovascular eye diseases including wAMD, DR/DME, glaucoma) and vascular-related diseases by utilizing its proprietary HuPhage Display Library platform.
Olinvacimab, anti-VEGFR2 neutralizing fully-human antibody, is our lead asset in Phase 2 stage for patients with mTNBC. Olinvacimab + Keytruda combination therapy in Phase 1b study for mTNBC patients delivered a clean safety profile with 50% ORR and 67% DCR.
PMC-403, anti-TIE2 agonizing mAb, normalizes leaky inflammatory pathological vasculature to healthy vasculature. Due to this MoA, IND for nAMD, DR/DME Phase 1 study has been submitted in December 2022.
PMC-309, anti-VISTA antagonizing mAb, can block negative immune checkpoint regulation by VISTA in pan-pH environment. IND submission for Phase 1 all-comers solid tumors will be submitted in Q2 of 2023.
Olinvacimab, anti-VEGFR2 neutralizing fully-human antibody, is our lead asset in Phase 2 stage for patients with mTNBC. Olinvacimab + Keytruda combination therapy in Phase 1b study for mTNBC patients delivered a clean safety profile with 50% ORR and 67% DCR.
PMC-403, anti-TIE2 agonizing mAb, normalizes leaky inflammatory pathological vasculature to healthy vasculature. Due to this MoA, IND for nAMD, DR/DME Phase 1 study has been submitted in December 2022.
PMC-309, anti-VISTA antagonizing mAb, can block negative immune checkpoint regulation by VISTA in pan-pH environment. IND submission for Phase 1 all-comers solid tumors will be submitted in Q2 of 2023.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1517948-1-JPG.jpg)
Ticker:
208340 (KOSDAQ)
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Daejeon
Company HQ Country:
Korea, Republic of
Year Founded:
2008
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Olinvacimab
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-YooJ.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved